<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903549</url>
  </required_header>
  <id_info>
    <org_study_id>JH-181698</org_study_id>
    <nct_id>NCT03903549</nct_id>
  </id_info>
  <brief_title>Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers</brief_title>
  <official_title>A Positron Emission Tomography (PET) Study to Investigate [18F]D6-FP-DTBZ ([18F]P17-059) for Potential Use as a Radioligand for Vesicular Monoamine Transporter (VMAT2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Five Eleven Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Five Eleven Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the initial safety profile of [18F]P17-059 in healthy volunteers
      including dosimetry determination, and compares regional brain uptake and kinetics of
      [18F]P17-059 in Parkinson's disease patients with regional brain uptake and kinetics of
      [18F]P17-059 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional brain uptake of [18F]P17-057 in Parkinson patients compared healthy volunteers</measure>
    <time_frame>0 - 90 minutes post injection</time_frame>
    <description>Quantitative estimates of [18F]P17-059 uptake in brain - SUV and non-displaceable Binding Potential</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative organ [18F]P17-059 activity for estimates of radiation absorbed dose and effective dose</measure>
    <time_frame>0 - 240 minutes post injection</time_frame>
    <description>Dosimetry</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Brain uptake and kinetics in Parkinson patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brain uptake and kinetics in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosimetry in healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]P17-059</intervention_name>
    <description>Injection of &lt; 10 mCi [18F]P17-059 followed by PET/CT scanning</description>
    <arm_group_label>Brain uptake and kinetics in Parkinson patients</arm_group_label>
    <arm_group_label>Brain uptake and kinetics in healthy volunteers</arm_group_label>
    <arm_group_label>Dosimetry in healthy volunteers</arm_group_label>
    <other_name>[18F]D6FP</other_name>
    <other_name>[18F]D6FPDTBZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria (Healthy Volunteers)

               1. Healthy non-smoking males and females, as determined by medical history, physical
                  examination, vital signs, clinical laboratory tests, and an electrocardiogram.

                  1.1 Male subjects and their child bearing potential partners must be willing to
                  use a reliable method of birth control for the duration of the study.

                  1.2 Female subjects who are of childbearing potential must agree to use an
                  adequate method of contraception for the duration of the study.

               2. Between 45-85 years old, inclusive.

               3. BMI between 18-32 kg/m2 inclusive.

               4. Have clinical laboratory test results within the reference ranges for the
                  population or results within acceptable deviations that are not considered by the
                  investigator to be clinically significant.

               5. All subjects and their partners of childbearing potential must commit to use two
                  methods of contraception, one of which must be a barrier method, from the time of
                  screening and throughout the study and until follow-up.

               6. Less than 195 cm (6 feet and 5 inches) tall in order to accommodate the whole
                  body scanning.

               7. Have sufficient venous access.

               8. Willing to give written informed consent and to comply with the study
                  restrictions.

          -  Inclusion criteria (PD patients)

               1. Signed and dated written informed consent.

               2. Male or Female.

               3. Age 45-90.

               4. Diagnosis of clinically established idiopathic PD consistent with the Movement
                  Disorder Society Clinical Diagnostic Criteria for Parkinson's disease (PD)
                  (Postuma, et al., 2014).

               5. BMI between 18-32 kg/m2 inclusive.

               6. Have clinical laboratory test results within the reference ranges for the
                  population or results within acceptable deviations that are not considered by the
                  investigator to be clinically significant.

               7. All subjects and their partners of childbearing potential must commit to use two
                  methods of contraception, one of which must be a barrier method, from the time of
                  screening and throughout the study and until follow-up.

               8. Less than 195 cm (6 feet and 5 inches) tall in order to accommodate the whole
                  body scanning.

               9. Have sufficient venous access.

              10. Absence of an established clinical movement disorder diagnosis other than
                  Parkinson's disease.

              11. Symptoms mild in intensity, this includes Hoehn &amp; Yahr ≤ 2 (Exceptions are
                  allowed for subjects who meet criteria for Hoehn &amp; Yahr stage 2/5 due to early
                  onset of postural instability and/or gait impairment out of proportion to his/her
                  other Parkinson signs and symptoms);

              12. Montreal Cognitive Assessment (MoCA) score ≥ 22;

              13. Can tolerate imaging visit procedures

              14. Willing to give written informed consent and to comply with the study
                  restrictions.

              15. Female patients must have had her last natural menstruation at least ≥24 months
                  prior to the Screening Visit or have been surgically sterilized prior to the
                  Screening Visit. Male patients must use two methods of contraception in
                  combination if his female partner is of childbearing potential; OR have been
                  surgically sterilized prior to the Screening Visit.

              16. In the opinion of the investigator based on medical history and physical
                  examination, can safely tolerate tracer administration and the scanning
                  procedures.

          -  exclusion criteria (Healthy volunteers)

               1. Are currently enrolled in or discontinued within the last 30 days from a clinical
                  trial involving an investigational drug or device (other than the study drug) or
                  are currently enrolled in any other type of medical research.

               2. Are currently experiencing neuropsychiatric illness or severe systemic disease
                  based on history and physical exam.

               3. Have participated in other research protocols in the last year such that
                  radiation exposure would exceed the annual limits.

               4. Pregnant or nursing women.

               5. History of head trauma with prolonged loss of consciousness (&gt;10 minutes) or any
                  neurological condition including stroke or seizure (excluding childhood febrile
                  seizure).

               6. History or presence of any clinically relevant hematological, hepatic,
                  respiratory, cardiovascular, renal, metabolic, endocrine, or CNS disease or other
                  medical conditions that are not well controlled, may put the subject at risk,
                  could interfere with the objectives of the study, or make the subject unsuitable
                  for participation in the study for any other reason in the opinion of the
                  principal investigator.

               7. Suffer from claustrophobia and would be unable to undergo MRI and PET scanning.

               8. Any confirmed significant allergic reactions against any drug, or multiple
                  allergies.

               9. Currently uses prescription medications, over-the-counter drugs or herbal
                  remedies such as St. Johns Wort) which cannot be discontinued 14 days (or &lt; 5
                  half-lives, whichever is longer), prior to the PET scan and throughout the study.
                  Exceptions include daily multiple vitamins.

          -  exclusion criteria (PD patients)

               1. Have a known CNS structural lesion such as stroke or tumor that likely accounts
                  for their symptoms;

               2. Have current clinically significant cardiovascular disease or clinically
                  important abnormalities on screening ECG (including but not limited to QTc &gt; 450
                  msec);

               3. Are currently taking medications that are known to cause QT-prolongation;

               4. Are currently taking medications with narrow therapeutic windows (e.g. warfarin
                  or other anticoagulant therapies);

               5. Are currently taking tetrabenazine (TBZ), valbenazine (Ingrezza), amphetamine
                  type drugs;

               6. Has taken tetrabenazine (TBZ) in the preceding 3 months;

               7. Have a current clinically significant endocrine or metabolic disease, pulmonary,
                  renal or hepatic impairment, or cancer (excluding localized basal cell carcinoma
                  and in situ prostate cancer) that would interfere with completion of the study;

               8. Have a recent history (within the past year) of alcohol or substance abuse or
                  dependence;

               9. Are females of childbearing potential who are not surgically sterile, not
                  refraining from sexual activity or not using reliable contraception. Females must
                  not be pregnant (negative serum beta-hCG at the time of screening and negative
                  urine beta-hCG on the day of imaging), must not be breastfeeding at screening,
                  must avoid becoming pregnant and use adequate contraceptive methods for 14 days
                  prior to and 24 hours after administration of 18F-D6-FPDTBZ for injection;

              10. Have had prior intracranial surgery; and

              11. Are receiving any investigational medications, or have participated in a trial
                  with investigational medications within the last 30 days.

              12. Contraindications of MRI. Incidental findings on MRI scans that are pathognomonic
                  for an active disease or pathological process which requires medical intervention
                  will be exclusionary.

              13. History of, or suffers from, claustrophobia or feels that he or she will be
                  unable to lie still on their back in the MRI or PET scanner.

              14. Urinary toxicology positive for nonprescribed substances

              15. Previous allergic reaction to the radiotracer ([18F]D6-FP-DTBZ) or substances of
                  similar chemical structure or excipients.

              16. Diagnosis of secondary parkinsonism caused by a brain tumor, cranial trauma, or
                  metabolic diseases (diabetes mellitus, hepatic insufficiency, alcoholism)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Medical Institutions</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

